Fennec Pharmaceuticals Inc FENC:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EDT
7.08quote price arrow up+0.39 (+5.83%)
Volume
120,164
52 week range
3.82 - 10.08
Loading...
  • Open6.83
  • Day High7.31
  • Day Low6.76
  • Prev Close6.69
  • 52 Week High10.08
  • 52 Week High Date11/12/21
  • 52 Week Low3.82
  • 52 Week Low Date12/01/21

Key Stats

  • Market Cap184.36M
  • Shares Out26.04M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.10
  • YTD % Change60.91

KEY STATS

  • Open6.83
  • Day High7.31
  • Day Low6.76
  • Prev Close6.69
  • 52 Week High10.08
  • 52 Week High Date11/12/21
  • 52 Week Low3.82
  • 52 Week Low Date12/01/21
  • Market Cap184.36M
  • Shares Out26.04M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta0.10
  • YTD % Change60.91

RATIOS/PROFITABILITY

  • EPS (TTM)-0.63
  • P/E (TTM)-11.29
  • Fwd P/E (NTM)-15.23
  • EBITDA (TTM)-15.846M
  • ROE (TTM)-87.08%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-9,504.12%
  • Debt To Equity (MRQ)39.92%

EVENTS

  • Earnings Date11/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Fennec Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Fennec Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical stage of development is PEDMARK. It announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the...
Khalid Islam Ph.D.
Independent Chairman of the Board
Rostislav Raykov
Chief Executive Officer, Director
Robert Andrade
Chief Financial Officer
Address
68 Tw Alexander Dr
PO Box 13628
Research Triangle Park, NC
27709
United States